biostudies-literatureUnknown14(5)Huang CFKaohsiung Medical UniversityKaohsiung Medical University Chung-Ho Memorial Hospital<h4>Background/aims</h4>Direct-acting antivirals (DAAs) are highly effective in treating hepatitis C virus (HCV) infection. The long-term hepatic and extrahepatic outcomes of DAAs in chronic hepatitis C (CHC) patients receiving curative antivirals are elusive.<h4>Methods</h4>CHC patients were retrieved from two phase III sofosbuvir-based clinical trials conducted from 2013-2014. Patients who achieved a sustained virological response have been followed prospectively for 5 years since 2016. A propensity score-matched interferon-based historical control with a 1:3 ratio was used for comparison. Quality of life (QoL) was measured by the SF-36, liver fibrosis was measured by electrography, and fibrosis-related markers were followed annually in the prospective cohort.<h4>Results</h4>A total of 1Infectious diseases and therapy1089-1101https://www.ebi.ac.uk/biostudies/studies/S-EPMC12084436biostudies-literatureLong-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study).PMC12084436Kao JHByun KSYoon SKPaik SWPeng CYHuang CFChen JJSheen ISYoun-Jae LeeKim YJYu MLAhn SHTak WYYim HJYeh MLKim YSLim YSTsai PCHsu YCChien RNBaek YHHu THWang HYChang TTChuang WLHeo JKim JHDai CYJeong SHHuang JFfalseLong-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study).<h4>Background/aims</h4>Direct-acting antivirals (DAAs) are highly effective in treating hepatitis C virus (HCV) infection. The long-term hepatic and extrahepatic outcomes of DAAs in chronic hepatitis C (CHC) patients receiving curative antivirals are elusive.<h4>Methods</h4>CHC patients were retrieved from two phase III sofosbuvir-based clinical trials conducted from 2013-2014. Patients who achieved a sustained virological response have been followed prospectively for 5 years since 2016. A propensity score-matched interferon-based historical control with a 1:3 ratio was used for comparison. Quality of life (QoL) was measured by the SF-36, liver fibrosis was measured by electrography, and fibrosis-related markers were followed annually in the prospective cohort.<h4>Results</h4>A total of 12025-01-01T00:00:00Z2025 May2026-05-29T17:02:48.948Z2026-04-08T05:25:51.598ZS-EPMC120844364020514510.1007/s40121-025-01145-y